Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Simon A. Woodcock
Observed names:
S. Woodcock,
S.A. Woodcock,
Simon A Woodcock,
Simon A. WOODCOCK,
Simon Woodcock,
Simon A. Woodcock
show all 6
Observed institutions:
AstraZeneca (United Kingdom),
National Center for Toxicological Research,
Manchester Academic Health Science Centre,
Cancer Research UK,
University of Manchester,
Cancer Research UK Manchester Institute,
Redx Pharma (United Kingdom)
show all 7
ORCID:
0000-0001-7363-757X
Observed ORCID:
0000-0001-7363-757X
OpenAlex ID:
A5003246050
The Rac activator STEF (Tiam2) regulates cell migration by microtubule‐mediated focal adhesion disassembly
2010
·
Claire Rooney
, Gavin White
, et al.
·
EMBO Reports
·
113
PDF
Src-Induced Disassembly of Adherens Junctions Requires Localized Phosphorylation and Degradation of the Rac Activator Tiam1
2009
·
Simon A. Woodcock
, Claire Rooney
, et al.
·
Molecular Cell
·
86
PDF
Inhibition of Wnt signalling by Notch via two distinct mechanisms
2021
·
Ahmet Acar
, Ana Hidalgo-Sastre
, et al.
·
Scientific Reports
·
70
PDF
Compensatory Flux Changes within an Endocytic Trafficking Network Maintain Thermal Robustness of Notch Signaling
2014
·
Hideyuki Shimizu
, Simon A. Woodcock
, et al.
·
Cell
·
70
PDF
Tiam1-Rac Signaling Counteracts Eg5 during Bipolar Spindle Assembly to Facilitate Chromosome Congression
2010
·
Simon A. Woodcock
, Helen J. Rushton
, et al.
·
Current Biology
·
59
PDF
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2022
·
Caroline Phillips
, Inder Bhamra
, et al.
·
Cancer Research Communications
·
40
A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?
2015
·
Jessica Taylor
, Simon Woodcock
·
SLAS DISCOVERY
·
39
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition
2022
·
Dustin J. Flanagan
, Simon A. Woodcock
, et al.
·
Pharmacology & Therapeutics
·
36
PDF
Generating Selective Leads for Mer Kinase Inhibitors—Example of a Comprehensive Lead-Generation Strategy
2021
·
J. Willem M. Nissink
, Sana Bazzaz
, et al.
·
Journal of Medicinal Chemistry
·
30
A Modified Tandem Affinity Purification Technique Identifies That 14-3-3 Proteins Interact with Tiam1, an Interaction Which Controls Tiam1 Stability
2009
·
Simon A. Woodcock
, Richard C. Jones
, et al.
·
Journal of Proteome Research
·
30
Alternative mechanisms of Notch activation by partitioning into distinct endosomal domains
2024
·
Hideyuki Shimizu
, Samira Hosseini-Alghaderi
, et al.
·
The Journal of Cell Biology
·
20
PDF
p120 Ras GTPase-activating protein associates with fibroblast growth factor receptors in Drosophila
2004
·
Simon A. WOODCOCK
, David A. HUGHES
·
Biochemical Journal
·
16
TheDrosophilaZO-1 protein Polychaetoid suppresses Deltex-regulated Notch activity to modulate germline stem cell niche formation
2017
·
Hideyuki Shimizu
, Marian B. Wilkin
, et al.
·
Open Biology
·
15
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
2021
·
N. Cook
, S. Blagden
, et al.
·
Annals of Oncology
·
11
Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer
2019
·
Caroline Phillips
, Inder Bhamra
, et al.
·
Cancer Research
·
11
Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.
2017
·
Inder Bhamra
, Nick Adams
, et al.
·
Journal of Clinical Oncology
·
10
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
2022
·
Scott Kopetz
, Van K. Morris
, et al.
·
Journal of Clinical Oncology
·
9
Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
2018
·
Inder Bhamra
, Richard Armer
, et al.
·
Cancer Research
·
9
37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
2024
·
N. Cook
, J.A. Bridgewater
, et al.
·
Annals of Oncology
·
7
PDF
Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer
2019
·
Simon Woodcock
, Inder Bhamra
, et al.
·
Cancer Research
·
5
Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
2024
·
Natalie Cook
, Sarah Blagden
, et al.
·
Cancer Research
·
3
RasGAP mediates neuronal survival inDrosophilathrough direct regulation of Rab5-dependent endocytosis
2014
·
Behzad Rowshanravan
, Simon A. Woodcock
, et al.
·
Journal of Cell Science
·
3
391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
2024
·
J.A. Bridgewater
, L. Chantrill
, et al.
·
Annals of Oncology
·
2
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors
2022
·
Natalie Cook
, Sarah Blagden
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Abstract 2566: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
2022
·
James Kelly
, Simon Woodcock
, et al.
·
Cancer Research
·
2
Show more works
View as search
Works count:
45
Citation count:
705
H-index:
13
I10-index:
16
Year
Topic
Type
